MedPath

Study of clot dissolving treatment for stroke that occurs during sleep

Phase 1
Conditions
Acute ischaemic stroke upon awakening (wake-up stroke)
Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Registration Number
EUCTR2014-000096-80-FI
Lead Sponsor
niversity or Tromsø
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
All
Target Recruitment
500
Inclusion Criteria

•Stroke symptoms on awakening that were not present before sleep
•Clinical diagnosis of stroke with limb weakness with NIHSS score >5, or dysphasia.
•Treatment with tenecteplase is possible within 4.5 hours of awakening
•Written consent from the patient, non-written consent from the patient (witnessed by non-participating health care personnel), or written consent from the nearest family member.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 100
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 400

Exclusion Criteria

•Age < 18 years
•Findings on plain CT that indicate that the patient is unlikely to benifit from treatment:
-Infarction comprising more than >1/3 of the middle cerebral artery territory on plain CT
-Intracranial haemorrhage, structural brain lesions which can mimic stroke (e.g cerebral tumour)
•Patient will be treated with intra-arterial interventions for proximal cerebral artery occlusion
•High risk of bleeding, e.g.:
-Major surgery, trauma or gastrointestinal or urinary tract haemorrhage within the previous 21 days, or arterial puncture at a non-compressible site within the previous 7 days.
-Any known defect in coagulation, e.g. current use of vitamin K antagonist with an INR > 1.7, or other oral anticoagulant, or heparins
-Known defect of clotting or platelet function (but patients on antiplatelet agents can be included)
-Ischaemic stroke in previous 2 weeks, previous intracranial haemorrhage, or known arteriovenous malformation or aneurysm
•Persistent blood pressure elevation (systolic =185 mmHg or diastolic =110 mmHg), despite blood pressure lowering treatment
•Blood glucose < 3.0 or > 20.0 mmol/L
•Childbearing potential, pregnancy, positive pregnancy test, breastfeeding
•Other serious or life-threatening disease before the stroke: severe mental or physical disability (e.g. Mini Mental Status score < 20, or modified Rankin Scale score = 3), or life expectancy less than 12 months
•Patient unavailability for follow-up (e.g. no fixed address)

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath